Send PM
Followers 186
Posts 14308
Boards Moderated 1
Alias Born 03/29/2014

Re: None

Monday, 12/19/2016 11:54:18 AM

Monday, December 19, 2016 11:54:18 AM

Post# of 542162
Linda Liau responds to investor concerns regarding 12/15/16 Seattle presentation. In an email exchange between an investor and Linda Liau, Dr. Liau offers clarification regarding her comments from the presentation.

Dear Dr. Liau: In your video last week (and also last year), your comments seemed quite positive about the patients living longer, but last week you also seemed to say that DCVax would not be able to get FDA approval. Is that what you really meant? How could that be the case if patients are living longer? Would love to have clarification on this issue

Thank you in advance for your time .
Xxxxxx xxxxxxxx

Dr. Liau's answer

Hi Xxxxxx,

Yes, the patients do seem to be living longer with DCVax; and no, I did not mean to say that DCVax would not get FDA approval. I was making the point that, whether or not the study fits a particular category endpoint, there should be a way to get approval if the data shows that the entire group of DCVax patients (in both arms) does better than concurrent/historical controls who have not gotten DCVax.

Hope this clarifies the issue.


Linda M. Liau, M.D., Ph.D., M.B.A.
Professor & Vice Chair of Neurosurgery

Director, UCLA Brain Tumor Program

UCLA Department of Neurosurgery
Sent from my iPhone

This investor doesn’t post on the boards, and decided to forward me the above email exchange with Dr. Liau regarding a question the investor had asked her in an email. The investor was concerned as a result of her Seattle presentation that Linda Liau was of the impression that DCVax-L would not be eligible for FDA approval despite the fact that these patients were all living longer.

Dr. Liau’s response to the query is important, and I don’t believe this person had actually anticipated receiving a response from her, let alone a response as quickly as it was given.

So this person forwarded the entire query and response to me because this investor felt what Dr. Liau wrote was very relevant to all other investors as well. And since this investor knows I do post on the boards, this seemed the best way to share it.

And I know a few of you will wonder why this person couldn’t just post it themselves. The answer is that this investor doesn’t post, has never posted, and most of you would not be familiar with this person anyway. The investor decided that having me post this exchange with Dr. Liau would be the best way to get out LL’s self-described clarification on this “issue” to all of us.

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Recent NWBO News

FEATURED InnerScope Hearing Technologies (OTC: INND) Launches Its iHEAR Brand of OTC Hearing Aids on Dec 1, 2022 8:00 AM

FEATURED Aduro Announces Completion of Mechanical Assembly of its R2 Plastic Reactor Dec 1, 2022 7:59 AM

Healixa Inc. Appoints Former Acting Secretary of Defense of The United States Christopher C. Miller to Its Advisory Board EMOR Dec 1, 2022 9:20 AM

Kona Gold Beverage, Inc's Gold Leaf Distribution Subsidiary Posts Record Revenue Month in November KGKG Dec 1, 2022 9:00 AM

Mullen Automotive Officially Closes on Acquisition of ELMS Assets, Takes Possession of Plant in Mishawaka, Ind., All Intellectual Property and Related Inventory MULN Dec 1, 2022 8:31 AM

HealthLynked Announces Points Reward Program for Online Medical Supplies Purchases HLYK Dec 1, 2022 8:00 AM

Fission 3.0 Intersects Off-Scale Mineralization in the First Follow Up Hole at PLN A1 Discovery FUU Nov 30, 2022 8:21 AM

Healixa Expands Advisory Board with Appointment of Accomplished C-Level Executive with History of Accelerating Profitable Growth EMOR Nov 29, 2022 9:26 AM

AgriFORCE Receives Patent Allowance from the United States Patent and Trademark Office Related to its Proprietary Process and Technologies for the UN(THINK) Foods Brand AGRI Nov 29, 2022 9:24 AM

Kona Gold Beverage, Inc Partners with Strategy & Execution Inc to Accelerate Beverage Growth in 2023 KGKG Nov 29, 2022 9:00 AM

Nextech AR CEO Evan Gappelberg Buys 250,000 Shares of Company Stock In Open Market Purchases NTAR Nov 29, 2022 7:15 AM

Goldshore Intersects Additional High-Grade Shears in the QES Zone at the Moss Lake Gold Project GSHR Nov 28, 2022 8:39 AM


Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM